REFERENCES
- Chen JJ, Pittock SJ, Flanagan EP, Lennon VA, Bhatti MT. Optic neuritis in the era of biomarkers. Surv Ophthalmol. 2019:S0039625719302462. https://linkinghub.elsevier.com/retrieve/pii/S0039625719302462. Accessed Nov 24, 2019.
- Optic Neuritis Study Group. The clinical profile of optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol. American Medical Association; 1991;109:1673–1678. http://jamanetwork.com/journals/jamaophthalmology/fullarticle/639424
- Narayan RN, McCreary M, Conger D, Wang C, Greenberg BM. Unique characteristics of optical coherence tomography (OCT) results and visual acuity testing in myelin oligodendrocyte glycoprotein (MOG) antibody positive pediatric patients. Mult Scler Relat Disord. 2019;28:86–90. https://linkinghub.elsevier.com/retrieve/pii/S2211034818305194.
- Jarius S, Paul F, Ruprecht K, Wildemann B. Low vitamin B12 levels and gastric parietal cell antibodies in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J Neurol. 2012;259:2743–2745. http://link.springer.com/10.1007/s00415-012-6677-1. Accessed February 2, 2020.
- Tornes L, Ortega MR, Delgado S, Rammohan KW. Vitamin B12 deficiency mimicking NMO spectrum disorder. Mult Scler J. SAGE Publications Ltd STM; 2012;18:1659–1660. doi:10.1177/1352458512452923.
- Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–2112. doi:10.1016/S0140-6736(04)17551-X.
- Seay M, Rucker JC. Neuromyelitis optica: review and utility of testing aquaporin-4 antibody in typical optic neuritis. Asia-Pac J Ophthalmol. 2019;7:229–234. https://journals.lww.com/apjoo/Fulltext/2018/07000/Neuromyelitis_Optica__Review_and_Utility_of.3.aspx.
- Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485–1489. doi:10.1212/01.wnl.0000216139.44259.74.
- Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–189. doi:10.1212/WNL.0000000000001729.
- Prasad S, Chen J. What you need to know about AQP4, MOG, and NMOSD. Semin Neurol. 2019;39:718–731. http://www.thieme-connect.de/DOI/DOI?10.1055/s-0039-3399505.
- Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO. Neurology. 2012;78:665–671. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286228/. Accessed February 16, 2020.
- Im K, Mareninov S, Diaz MFP, Yong WH. An introduction to performing immunofluorescence staining. In: Yong WH, ed. Biobanking.New York: Springer New York; 2019:299–311. http://link.springer.com/10.1007/978-1-4939-8935-5_26
- Granieri L, Marnetto F, Valentino P, et al. Evaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serology. Reindl M, editor. PLoS ONE. 2012;7:e38896. https://dx.plos.org/10.1371/journal.pone.0038896. Accessed March 12, 2020.
- Prain K, Woodhall M, Vincent A, et al. AQP4 antibody assay sensitivity comparison in the era of the 2015 diagnostic Criteria for NMOSD. Front Neurol. 2019;10:1028. https://www.frontiersin.org/article/10.3389/fneur.2019.01028/full. Accessed February 16, 2020.
- Petzold A, Wattjes MP, Costello F, et al. The investigation of acute optic neuritis: a review and proposed protocol. Nat Rev Neurol. 2014;10:447–458. http://www.nature.com/articles/nrneurol.2014.108.
- Borisow N, Mori M, Kuwabara S, Scheel M, Paul F. Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front Neurol. 2018;9:888. https://www.frontiersin.org/article/10.3389/fneur.2018.00888/full. Accessed November 29, 2019.
- Yang J, Kim SM, Kim Y-J, et al. Accuracy of the fluorescence-activated cell sorting assay for the aquaporin-4 antibody (AQP4-Ab): comparison with the commercial AQP4-Ab assay kit. Plos One. Public Library of Science. 2016;11:e0162900. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0162900
- Yang J, Kim SM, Kim Y-J, et al. Correction: accuracy of the fluorescence-activated cell sorting assay for the aquaporin-4 antibody (AQP4-Ab): comparison with the commercial AQP4-Ab assay kit. Plos One. Public Library of Science. 2017;12:e0180379. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0180379
- Liu C, Zhu M, Wang Y. Human serum anti-aquaporin-4 immunoglobulin G detection by cell-based assay. JoVE J Vis Exp. 2019;e59014. http://www.jove.com/video/59014/human-serum-anti-aquaporin-4-immunoglobulin-g-detection-cell-based. Accessed March 21, 2020.
- Waters P, Reindl M, Saiz A, et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2016;87:1005–1015. http://jnnp.bmj.com/lookup/doi/10.1136/jnnp-2015-312601. Accessed February 16, 2020.
- Long Y, Liang J, Zhong R, et al. Aquaporin-4 antibody in neuromyelitis optica: re-testing study in a large population from China. Int J Neurosci. 2017;127:790–799. https://www.tandfonline.com/doi/full/10.1080/00207454.2016.1259226. Accessed February 16, 2020.
- Marignier R, Bernard-Valnet R, Giraudon P, et al. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology. 2013;80:2194–2200. http://www.neurology.org/cgi/doi/10.1212/WNL.0b013e318296e917. Accessed February 16, 2020.
- Fujihara K, Leite MI. Seronegative NMO: A sensitive AQP4 antibody test clarifies clinical features and next challenges. Neurology. 2013;80:2176–2177. http://n.neurology.org/content/80/24/2176. Accessed February 3, 2020.
- Kezuka T, Ishikawa H. Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis. Jpn J Ophthalmol. 2018;62:101–108. http://link.springer.com/10.1007/s10384-018-0561-1. Accessed November 24, 2019.
- Jarius S, Paul F, Aktas O, et al. MOG-encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflam. 2018;15:1144–1152. http://link.springer.com/10.1007/s00115-018-0607-0. Accessed November 29, 2019.
- Loos J, Pfeuffer S, Pape K, et al. MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation. J Neurol. 2020;267:1632–1642. http://link.springer.com/10.1007/s00415-020-09755-x.
- Dale RC, Tantsis EM, Merheb V, et al. Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurol - Neuroimmunol Neuroinflam. 2014;1:e12. http://nn.neurology.org/lookup/doi/10.1212/NXI.0000000000000012
- Reindl M, Schanda K, Woodhall M, et al. International multicenter examination of MOG antibody assays. Neurol - Neuroimmunol Neuroinflam. 2020;7:e674. http://nn.neurology.org/lookup/doi/10.1212/NXI.0000000000000674
- Ducloyer J-B, Caignard A, Aidaoui R, et al. MOG-Ab prevalence in optic neuritis and clinical predictive factors for diagnosis. Br J Ophthalmol. 2019:bjophthalmol-2019-314845. http://bjo.bmj.com/lookup/doi/10.1136/bjophthalmol-2019-314845. Accessed November 24, 2019.
- Waters P, Woodhall M, O’Connor KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol - Neuroimmunol Neuroinflam. 2015:2(3)e89.
- Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016;13. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084340/
- Kunchok A, Chen JJ, McKeon A, Mills JR, Flanagan EP, Pittock SJ. Coexistence of myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies in adult and pediatric patients. JAMA Neurol. 2020;77:257. https://jamanetwork.com/journals/jamaneurology/fullarticle/2753236.
- Igarashi N, Sawamura H, Kaburaki T, Aihara M. Anti-collapsing response-mediating protein-5 antibody–positive paraneoplastic perioptic neuritis without typical neurological symptoms. Neuro-Ophthalmol. 2016;41:24–29. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278783/.
- Yu Z, Kryzer TJ, Griesmann GE, Kim -K-K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001;49:146–154. http://onlinelibrary.wiley.com/doi/abs/10.
- Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol. 2003;54:38–50. http://onlinelibrary.wiley.com/doi/abs/10.1002/ana.10587. Accessed March 22, 2020.
- Sabater L, Saiz A, Dalmau J, Graus F. Pitfalls in the detection of CV2 (CRMP5) antibodies. J Neuroimmunol. 2016;290:80–83. https://linkinghub.elsevier.com/retrieve/pii/S016557281530076X.